Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ODTXthis companyOdyssey Therapeutics, Inc.	$19.19	-3.05×	-0.93×	152.07×	-3.03×	-100.4%	100.0%	-5415.2%	-4994.9%	30.4%	-64.4%	-28.9%	-0.06×	0.1×	-9,479.76×	7.2×	0.0%	—	—	2	C+
ACRSAclaris Therapeutics, Inc.	$4.22	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
ALMSAlumis Inc.	$6.39	-4.21×	27.54×	345.07×	-33.2×	-85.0%	85.5%	-1776.3%	-1011.7%	-80.8%	-120.2%	-4.5%	0.12×	0.21×	0×	4.34×	0.0%	2	0.06	1	C-
ANABAnaptysBio, Inc.	$47.82	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
IMUXImmunic, Inc.	$8.02	-0.86×	-12.46×	0×	-0.7×	-91.8%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.39	2	C
ORKAOruka Therapeutics, Inc.	$105.31	-13.12×	2.93×	0×	-12.7×	-99.1%	0.0%	0.0%	0.0%	-22.3%	-25.8%	-6.4%	0×	0.43×	0×	22.37×	0.0%	2	155.06	2	C
Peer median	—	-5.68×	3.58×	3.83×	-5.45×	-99.1%	73.3%	0.0%	-5.6%	-35.6%	-25.8%	-6.4%	0.02×	0.21×	0×	5.28×	0.0%	2	0.06	2	—